Platelet-activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis
Platelet-activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis
复制标题
DOI：
10.1159/000188948
复制
发表时间：
1996-04-01
期刊：
影响因子：
2.5
通讯作者：
Ziroyiannis, P
中科院分区：
文献类型：
--
作者：
Iatrou, C;Moustakas, G;Ziroyiannis, P
血小板活化因子(PAF)是一类新的脂类化学炎性介质，被称为乙酰甘油醚磷酰胆碱。虽然PAF与肾脏损伤有关，但其在肾脏免疫损伤中的作用尚不清楚。本文研究了原发性肾小球肾炎(PGN)患者血浆和尿液中PAF水平及血清和肾组织(皮质、C和髓质)中的乙酰水解酶(AH)活性。同时测定正常志愿者血、尿PAF水平、血清AH活性以及肾切除患者(对照组)正常肾实质(C、M)的AH活性。我们的结果显示，与正常志愿者相比，PGN患者血浆和尿液中PAF水平以及血清中AH活性均升高。与正常肾组织相比，这些患者皮质中的AH活性降低。我们认为，PGN患者血清中AH活性的升高可能是由于肾组织中PAF的高生成和低降解，一方面导致血浆和尿液中PAF水平的升高，另一方面通过底物(PAF)的可获得性而导致血清AH活性的增强。这些数据为了解PAF及其降解酶在PGN中的动态平衡提供了新的知识。
Platelet-activating factor (PAF) belongs to a new class of lipid chemical inflammatory mediators described as acetyl glyceryl ether phosphorylcholine. Although PAF has been implicated in kidney injury, its role in renal immune injury has not been clearly defined yet. We studied the levels of PAF in the plasma and urine and acetylhydrolase (AH) activities in serum and in renal tissue (cortex, C and medulla, M) in patients with primary glomerulonephritis (PGN). PAF levels in the plasma and urine and AH activity in serum of normal volunteers as well as AH activities in normal renal parenchyma (C and M) from nephrectomized patients (served as control) were also measured. Our results demonstrate increased PAF levels in the plasma and urine as well as increased AH activity in serum in patients with PGN in comparison to normal volunteers. AH activity in cortex of those patients was diminished compared to normal kidney tissue. We propose that the enhanced AH activity in serum in patients with PGN could be due to hyperproduction and low degradation of PAF in nephritic tissue which on one hand results in enhanced PAF levels in the plasma and in urine and on the other hand results in enhanced serum AH activity by virtue of substrate (PAF) availability. These data provide new knowledge in the homeostasis of PAF and its degrative enzyme in the setting of PGN.